Early Treatment of Heart Failure: a Non-interventional Observational Study Program of Patients With Heart Failure and Initiated on Dapagliflozin (EVOLUTION-HF - GREECE)
Latest Information Update: 10 Feb 2025
Price :
$35 *
At a glance
- Drugs Dapagliflozin (Primary)
- Indications Heart failure
- Focus Therapeutic Use
- Acronyms EVOLUTION-HF
- Sponsors AstraZeneca
- 07 Feb 2025 Status changed from active, no longer recruiting to completed.
- 30 Nov 2023 Status changed from recruiting to active, no longer recruiting.
- 16 Jan 2023 Status changed from not yet recruiting to recruiting.